S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
Biden's Plan to Confiscate Your Cash? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:STSA

Satsuma Pharmaceuticals - STSA News Headlines

$5.88
-0.12 (-2.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.84
$5.99
50-Day Range
$2.90
$6.10
52-Week Range
$2.51
$6.52
Volume
38,135 shs
Average Volume
61,807 shs
Market Capitalization
$185.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Get Satsuma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter.

STSA Media Mentions By Week

STSA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

STSA
News Sentiment

-0.08

0.63

Average
Medical
News Sentiment

STSA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

STSA Articles
This Week

4

0

STSA Articles
Average Week



SourceHeadline
MarketBeat logoSatsuma Pharmaceuticals (NASDAQ:STSA) Stock Crosses Above 200-Day Moving Average of $4.10
americanbankingnews.com - August 14 at 6:08 AM
finance.yahoo.com logoDoes Satsuma Pharmaceuticals (STSA) Have the Potential to Rally 90% as Wall Street Analysts Expect?
finance.yahoo.com - August 12 at 4:08 PM
MarketBeat logoSatsuma Pharmaceuticals (NASDAQ:STSA) Stock Price Crosses Above Two Hundred Day Moving Average of $4.06
americanbankingnews.com - August 5 at 2:46 AM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
finance.yahoo.com - August 2 at 10:40 AM
MarketBeat logoHead to Head Contrast: Propanc Biopharma (OTCMKTS:PPCB) and Satsuma Pharmaceuticals (NASDAQ:STSA)
americanbankingnews.com - July 28 at 3:06 AM
MarketBeat logoSatsuma Pharmaceuticals (NASDAQ:STSA) & Propanc Biopharma (OTCMKTS:PPCB) Head-To-Head Comparison
americanbankingnews.com - July 28 at 3:04 AM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific Meeting
finance.yahoo.com - June 9 at 7:42 AM
benzinga.com logoSatsuma Pharmaceuticals (NASDAQ:STSA), Analyst Ratings, Price Targets, Predictions
benzinga.com - May 21 at 2:26 AM
finance.yahoo.com logoMizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target
finance.yahoo.com - May 13 at 5:39 PM
finance.yahoo.com logoWill Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
finance.yahoo.com - May 13 at 5:39 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 11 at 8:57 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
finance.yahoo.com - May 10 at 7:05 PM
seekingalpha.com logoSatsuma Pharmaceuticals GAAP EPS of -$0.49
seekingalpha.com - March 17 at 8:36 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights
finance.yahoo.com - March 15 at 6:57 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting
finance.yahoo.com - March 3 at 4:57 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 8 at 2:04 PM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Satsuma Pharmaceuticals, Inc.'s (NASDAQ:STSA) Share Registry?
finance.yahoo.com - January 24 at 3:04 PM
nasdaq.com logoSatsuma Pharmaceuticals, Inc. Common Stock (STSA)
nasdaq.com - January 12 at 9:03 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 8:14 PM
finance.yahoo.com logoCyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors
finance.yahoo.com - November 9 at 3:13 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences
finance.yahoo.com - October 28 at 8:53 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
finance.yahoo.com - October 12 at 7:22 PM
finance.yahoo.com logoSTSA Oct 2021 2.500 put
finance.yahoo.com - September 28 at 10:59 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 28 at 5:58 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 6:07 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
finance.yahoo.com - August 10 at 5:29 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
finance.yahoo.com - July 28 at 5:40 PM
finance.yahoo.com logoAre Institutions Heavily Invested In Satsuma Pharmaceuticals, Inc.'s (NASDAQ:STSA) Shares?
finance.yahoo.com - July 27 at 11:28 AM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at SVB Leerink’s CNS Forum
finance.yahoo.com - June 22 at 6:33 PM
baystreet.ca logoSatsuma Rockets on Drug Tests
baystreet.ca - June 17 at 1:04 PM
markets.businessinsider.com logoSatsuma Pharma Reports Positive Results Early-stage Study Of STS101
markets.businessinsider.com - June 16 at 8:03 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
finance.yahoo.com - June 16 at 8:03 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights
finance.yahoo.com - May 11 at 8:05 PM
finance.yahoo.com logoWhy Earnings Season Could Be Great for Satsuma Pharmaceuticals (STSA)
finance.yahoo.com - May 10 at 3:05 PM
finance.yahoo.com logoSatsuma Posts Wider-Than-Feared Quarterly Loss
finance.yahoo.com - March 26 at 8:14 AM
finance.yahoo.com logoSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
finance.yahoo.com - March 25 at 8:27 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 10 at 8:27 AM
finance.yahoo.com logoSatsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine
finance.yahoo.com - March 1 at 1:42 PM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces $80 Million Private Placement Financing
finance.yahoo.com - March 1 at 8:41 AM
finance.yahoo.com logoSatsuma Pharmaceuticals Announces Updated STS101 Development Plan
finance.yahoo.com - March 1 at 8:41 AM
finance.yahoo.com logoWhat Kind Of Investors Own Most Of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA)?
finance.yahoo.com - January 25 at 6:29 PM
finance.yahoo.com logoIs STSA A Good Stock To Buy Now?
finance.yahoo.com - December 7 at 11:34 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 24 at 7:21 PM
finance.yahoo.com logoSatsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
finance.yahoo.com - November 2 at 5:19 PM
nasdaq.com logoSatsuma Pharmaceuticals Enters Oversold Territory
nasdaq.com - October 6 at 7:31 AM
seekingalpha.com logoSatsuma: Not All Over For Migraine Treatment Despite Trial Failure
seekingalpha.com - September 25 at 7:19 PM
marketwatch.com logoNetworkNewsBreaks - Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) Featured in Mizuho Securities Research Report
marketwatch.com - September 12 at 7:38 PM
finance.yahoo.com logoSatsuma Plunges on Disappointing Data on Migraine Treatment
finance.yahoo.com - September 11 at 3:01 PM
seekingalpha.com logoAnalysts bails on Satsuma Pharma after underwhelming STS101 data in migrane
seekingalpha.com - September 11 at 10:00 AM
seekingalpha.com logoAnalysts bail on Satsuma Pharma after STS101 flop
seekingalpha.com - September 11 at 10:00 AM
Get Satsuma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:STSA) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.